PharmaShots | Incisive News in 3 Shots

Subscribe Now

Juvenile idiopathic arthritis

Innovent's Sulinno (biosimilar- adalimumab) Receive NMPA's Approval for Polyarticular Juvenile Idiopathic Arthritis

Innovent's Sulinno (biosimilar- adalimumab) Receive NMPA's Approval for Polyarticular Juvenile Idiopathic Arthritis

November 23, 2020

Merck's Brenzys (etanercept- biosimilar) Receives Health Canada Approval for Multiple Indications

Merck's Brenzys (etanercept- biosimilar) Receives Health Canada Approval for Multiple Indications

September 16, 2020

Cadila to Launch its Cadalimab (biosimilar- adalimumab) in India

Cadila to Launch its Cadalimab (biosimilar- adalimumab) in India

August 28, 2020

Lupin and Mylan Launch Nepexto (biosimilar- etanercept) in Germany

Lupin and Mylan Launch Nepexto (biosimilar- etanercept) in Germany

August 27, 2020

PharmaShots' Key Highlights of First Quarter 2019

PharmaShots' Key Highlights of First Quarter 2019

August 4, 2019

Lupin and YL Biologics' Etanercept Biosimilar (YLB113) Receive PMDA's Approval for Moderate-to-Severe Rheumatoid Arthritis (RA) and Juvenile Idiopathic Arthritis (JIA) in Japan

Lupin and YL Biologics' Etanercept Biosimilar (YLB113) Receive PMDA's Approval for Moderate-to-Severe Rheumatoid Arthritis (RA) an...

March 26, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us